메디채널

주메뉴 바로가기
본문 바로가기

기상청 제공

닫기

라이프

CMEF 2025: 의료 및 보건 산업의 전방위적ㆍ고품질 발전 촉진

[ 메디채널 김갑성 기자 ] 광저우, 중국 2025년 9월 1일 -- 제92회 중국국제의료기기박람회(China International Medical Equipment Fair, CMEF 2025) 하반기(가을) 행사가 9월 26일부터 29일까지 광저우 중국수출입상품교역전시관(China Import and Export Fair Complex, 캔톤 페어 전시장)에서 열릴 예정이다. '건강, 혁신, 협업(Health, Innovation, Collaboration)'을 주제로 한 이번 박람회는 글로벌 헬스케어 업계를 한자리에 모아 고품질 개발을 위한 새로운 기회를 모색한다. CMEF는 국제 최고 수준의 전시회로서 업계 전반의 전 세계 이해관계자를 결집시키며 혁신 기술 전시, 파트너십 및 브랜드 협력, 학술 교류, 트렌드 인사이트, 교육을 통해 글로벌 헬스케어의 고품질 성장을 견인한다. CMEF 2025는 약 20만㎡ 규모로 열리며 약 4000개 기업과 12만 명의 전문가가 참가할 예정이다. 이번 박람회는 의료 영상, 체외 진단, 수술 로봇, 스마트 헬스케어 등 28개 테마 존을 구성해, 연구개발부터 최종 사용자 응용
- 김갑성 기자
- 2025-09-01 21:50
Norma Completes Quantum AI Algorithm Validation on NVIDIA

[ 메디채널 김갑성 기자 ] "Quantum AI up to 73x Faster on NVIDIA CUDA-Q" Norma, a quantum computing company, has validated the performance of quantum AI algorithms using NVIDIA CUDA-Q. By running these algorithms for drug development on CUDA-Q, Norma observed computational speeds up to 73 times faster. The company has secured use cases for quantum AI in drug development and plans to expand validation efforts into various fields. SEOUL, South Korea, Sept. 1, 2025 -- Quantum computing company Norma (CEO Hyunchul Jung, www.norma.co.kr) has achieved over 73× faster
- 김갑성 기자
- 2025-09-01 21:00
AMI Pharm's AYP-101 Shows Promise in Phase 2 Trial, Signaling a Breakthrough in Nonsurgical Fat Reduction

AMI Pharm's 'AYP-101' Sets to Become a New Leader in Nonsurgical Fat Reduction with Phase 2 Trial Success 'AYP-101,' a Promising Nonsurgical Solution, Has Its Clinical Results Published in Clinical Therapeutics 'AYP-101' Demonstrates Superior Safety and Efficacy, Poised to Change the Paradigm of Submental Fat Reduction SEOUL, South Korea, Sept. 1, 2025 -- AMI Pharm's novel injectable drug, AYP-101, has shown promising results in a Phase 2 clinical trial for the reduction of submental fat (SMF), commonly known as a double chin. The clinical data from the trial was recen
- 김갑성 기자
- 2025-09-01 21:00
아크로바이오시템즈-다안바이오테라퓨틱스, 정밀 면역항암제 개발 위한 전략적 MOU 체결

[ 메디채널 김갑성 기자 ] 서울 대한민국 2025년 9월 1일 -- 글로벌 바이오텍 기업 아크로바이오시스템즈(ACROBiosystems)와 임상 단계 바이오기업 다안바이오테라퓨틱스(Daan Biotherapeutics)가 정밀 면역항암제 개발을 위한 전략적 양해각서(MOU)를 체결했다고 밝혔다. 이번 협약을 통해 양사는 고기능성 바이오시약의 안정적 공급, 면역항암제 개발을 위한 기술 협력, 공동 연구 및 데이터 공유 등 다각적 협력 체계를 구축하고, 정밀 면역치료제의 연구개발 및 상용화를 가속화할 계획이다. 아크로바이오시스템즈는 재조합 단백질, 키트, 항체, 과학 서비스 등을 제공하는 바이오텍 기업으로, 신약 개발에 혁신적인 솔루션을 제공하고 있다. 특히 세포유전자 치료제의 CMC 단계를 위해, 고품질의 GMP 등급 원료 및 품질관리(QC) 솔루션을 포함하는 Resilient Supply™ 라는 자체 브랜드를 론칭하여 생산 유연성과 규제 준수 측면에서 고객사의 니즈를 충족시키고 있다. 또한, 스마트 모듈형 설계와 ISO 9001/GMP 인증을 갖춘 GMP 생산 기지를 보유하여, 사이토카인, 세포치료제 활성화용 항
- 김갑성 기자
- 2025-09-01 16:10
Data4Life announces the appointment of Dr. Ben Illigens as new CEO by the Hasso Plattner Foundation

POTSDAM, Germany, Sept. 1, 2025 -- Data4Life announces that the Hasso Plattner Foundation, as the supporting foundation of the organization, has appointed Dr. Ben Illigens as its new Chief Executive Officer (CEO). He succeeds Christian Weiss, who has shaped the development phase of Data4Life since 2017 and will continue to advise the organization in a consulting role. With more than 15 years of experience at the intersection of clinical research, digital transformation, and global health initiatives, Dr. Illigens brings extensive expertise in neurology, oncology, digital health strateg
- 김갑성 기자
- 2025-09-01 16:00
Introducing FitTransformer: The World's First Modular Smart Gym That Transforms Your Home Workouts

PHOENIX, Sept. 1, 2025 -- Today marks the official launch of FitTransformer, a revolutionary fitness brand redefining how people train at home. Combining cutting-edge engineering, space-saving design, and intelligent performance tracking, FitTransformer introduces the first modular system that transforms seamlessly between cardio and strength training—without taking up an entire room. "We created FitTransformer to eliminate the complexity, clutter, and cost of traditional gym equipment," says Sam, Founder and CEO of FitTransformer. "Whether you live in a studio o
- 노기식 기자
- 2025-09-01 16:00
Berlin Heals Holding AG Successfully Raises Over 5Million USD Round for Advancing New Less Invasive Approaches

ZUG, Switzerland, Sept. 1, 2025 -- Berlin Heals Holding AG, a MedTech company, is developing a novel treatment to reverse remodel and recover from Heart Failure. After a successful First-In-Human study in 2019 followed by sustaining long-term results and a successful Randomized Controlled Trial completed in 2024, the company has been developing a new approach to implant the device less invasively in an outpatient cardiac cath lab procedure. The implant consists of two electrodes connected to an implantable generator that provides constant direct microcurrent across the
- 김갑성 기자
- 2025-09-01 15:00
Rosti to Showcase Next-Generation Medical Manufacturing Solutions at MedTec China 2025

SHANGHAI, Sept. 1, 2025 -- Shanghai, September 24–26, 2025 – Stand 1D402 Rosti Integrated Manufacturing Solutions (Suzhou) Co., Ltd., part of the Rosti Group, will highlight its expanding medical device capabilities at MedTec China 2025, showcasing advanced medical injection moulding, turnkey assembly, and innovative prototyping solutions that meet the most stringent international medical standards. Pioneering Medical Device Manufacturing As a trusted CDMO partner, Rosti delivers end-to-end solutions—from concept to commercialization. Leveraging deep industry expe
- 김갑성 기자
- 2025-09-01 14:53
CMEF 2025: Promoting Holistic and High-Quality Development of Medical and Health Industry

GUANGZHOU, China, Sept. 1, 2025 -- The 92nd China International Medical Equipment Fair (CMEF 2025) Autumn Exhibition is set to take place from September 26 to 29 at the China Import and Export Fair Complex (Canton Fair Complex) in Guangzhou. Themed "Health, Innovation, Collaboration," the tradeshow will bring together the global healthcare industry to explore new opportunities for high-quality development. As an international top-tier exhibition covering the entire industry chain, CMEF unites global stakeholders to drive high‑quality healthcare growth through innovati
- 김갑성 기자
- 2025-09-01 13:06
Jenscare, releases 2025H1 interim results

BEIJING, Sept. 1, 2025 -- Jenscare Scientific Co., Ltd. ("Jenscare" or the "Company") (HKEX: 9877), an innovative medical device company with TTVR breakthroughs, achieved milestones in its product portfolio globally, and just released its interim results for 2025H1 ended June 30, 2025. Business Overviews: In 2025H1, significant progress was achieved across its product pipeline in the interventional treatment for tricuspid, aortic and mitral valve diseases, establishing a diversified and high-potential product portfolio. More importantly, the Company continue
- 황정호 기자
- 2025-09-01 13:00

이전

71 72 73 74 75 76 77 78 79 80

많이 본 기사

최근기사

2025-11-05_WED

발행인 : 최희정 | 편집인 : 김갑성 |
등록번호: 서울특별시 아53302 | 등록일 2020-09-25 | 전화번호 02-565-7119 |
주소 : 서울특별시 강남구 영동대로 602, 6층 E115 (삼성동)
Copyright @메디채널 Corp. All rights reserved.

UPDATE: 2025년 11월 05일 09시 20분